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Down syndrome (DS) is mostly caused by a trisomy of the entire Chromosome 21 (Trisomy
21, T21). Here, we use SWATH mass spectrometry to quantify protein abundance and protein
turnover in ﬁbroblasts from a monozygotic twin pair discordant for T21, and to proﬁle protein
expression in 11 unrelated DS individuals and matched controls. The integration of the steady-
state and turnover proteomic data indicates that protein-speciﬁc degradation of members of
stoichiometric complexes is a major determinant of T21 gene dosage outcome, both within
and between individuals. This effect is not apparent from genomic and transcriptomic data.
The data also reveal that T21 results in extensive proteome remodeling, affecting proteins
encoded by all chromosomes. Finally, we ﬁnd broad, organelle-speciﬁc post-transcriptional
effects such as signiﬁcant downregulation of the mitochondrial proteome contributing to T21
hallmarks. Overall, we provide a valuable proteomic resource to understand the origin of DS
phenotypic manifestations.
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Down syndrome (DS) is caused by the presence of asupernumerary chromosome 21 (Chr21). DS is amongthe most prevalent genetic disorders, occurring in ~1 in
750 newborns. The phenotypic manifestation of DS, which
includes intellectual disability, congenital heart defects, and
increased occurrence of Alzheimer’s disease, is highly variable
across individuals1. The molecular mechanisms underlying the
phenotypic manifestations are still poorly understood. A simple
working hypothesis suggests that human Chr21 genes display
altered expression in individuals with T21 due to genome dosage
imbalance. Those dosage-sensitive Chr21 genes showing
increased expression by about 1.5-fold are expected to contribute
to the DS phenotype, whereas dosage insensitive genes are not1.
Recent transcript-centric studies were directed toward the iden-
tiﬁcation of dosage-sensitive Chr21 genes2–5. Transcriptome
proﬁles have been reported for various human tissues4, 6 and
mouse models trisomic for syntenic regions of Chr211,8.
Although the impact of T21 on the transcriptome has been
relatively well studied, we lack understanding of how T21 affects
the proteome. A review of recent work integrating genomic,
transcriptomic, and proteomic data has revealed that the effect
of copy number variations (CNVs) on protein levels is much
more complex than previously anticipated9. For example, studies
of cancer cells and yeast show that many CNVs resulting
in messenger RNA (mRNA) changes only weakly inﬂuence
corresponding protein levels9–12. Since DS is the prototype of
a chromosome gain CNV, herein we study the proteomic effects
of T21.
Skin ﬁbroblasts have been used to study gene dosage at the
transcript level for T21 since 197913, but to date no proteomic
T21 data have been available for this cell type. We herein study
the proteomes from skin ﬁbroblasts from 11 genetically unrelated
DS individuals and 11 controls. Additionally, we include ﬁbro-
blasts from an extremely rare pair of monozygotic (MZ) twins
discordant for T2114. This unique design of our study allows us to
compare the proteomic impact of T21 in a genetically identical
background to the impact observed in genetically distinct
individuals.
The primary aim of our study is to analyze T21-associated
proteome changes. However, the expected relatively small protein
level fold changes caused by the 1.5-fold gene dosage increase
poses a technical challenge for current proteomics technologies.
Indeed, previous protein measurements of DS cells, mainly
facilitated by antibody-based methods, only identiﬁed marginal
overexpression of a few proteins coded on Chr2115–17. To
circumvent this limitation, we apply SWATH mass spectrometry
(SWATH-MS), a recently developed, massively parallel protein
targeting technique, which features high accuracy and reprodu-
cibility in protein quantiﬁcation18–20. Additionally, we apply
pulsed SILAC (pSILAC)21–23 to quantify the turnover of corre-
sponding proteins and to further reveal mechanisms of proteome
adaptation. The integrative data reveal two principal responses to
the perturbation caused by T21: the ﬁrst is protein-speciﬁc
degradation, maintaining stoichiometric stability in heteromeric
protein complexes both within and across individuals, and the
second is organelle-speciﬁc proteostasis.
Results
A high-quality quantitative T21 proteome data set. To accu-
rately quantify the proteomic changes in DS, we used SWATH-
MS18 to analyze the proteome of fetal skin primary ﬁbroblasts
derived from 11 DS and 11 unrelated, sex and age-matched
normal control (N) individuals4 (hereafter, “unrelated samples”,
Fig. 1a, b; Supplementary Data 1), each with two experimental
replicates. Additionally, we analyzed a pair of MZ twins dis-
cordant for T21 (namely T2N and T1DS) for which tran-
scriptomic data was previously reported14. For each twin two
independent cell cultures, three experimental replicates were
analyzed, resulting in six proteomic proﬁles per individual
(Supplementary Fig. 1).
The resulting SWATH-MS data were processed with Open-
SWATH24 and further aligned with TRIC25 by targeted signal
extraction, using mass spectrometric query parameters for 10,000
human proteins as prior information26. We were able to
reproducibly quantify 4056 unique proteins (SwissProt identities,
protein FDR= 0.01 controlled by Mayu27) across all samples.
Furthermore, we spiked heavy stable isotope-labeled peptide
standards for 20 “anchor proteins” into the T1DS and T2N
samples. This approach estimates the absolute abundances of all
identiﬁed proteins20. We additionally measured both twin and
unrelated sample sets via the process of dimethyl labeling of
T1DS 0 h
24 hLi
gh
t
H
ea
vy
0 h
24 hLi
gh
t
H
ea
vy
N
N
T21
T21
T1DS T2N
a
c
M
S2
in
te
ns
ity
SILAC light
SILAC heavy
(t1,t2,..t6)
0~24 h
SILAC light
SILAC heavy
(t1,t2,..t6)
0~24 h
.
.
.
.
.
.
.
.
.
.
.
.N =11 N =11
21 21
Unrelated Individuals
Monozygotic twins 
Time
m
/z
b
SWATH-MS: 4056 proteins
T21 N
Pulsed SILAC & SWATH-MS: 2201 proteins
M
S1
 in
te
ns
ity
H H
O
D D
O
T21
peptides+
M
S2
in
te
ns
ity
N
peptides
+
Dimethylation & SAX fractions: 5636 proteins
d
T2N
Fig. 1 Proteome and proteostasis investigation on T21 ﬁbroblast cells. a Fibroblast cells collected from a pair of monozygotic (MZ) twins discordant for
Trisomy 21 (T21), together with 11 unrelated T21 individuals bearing Down syndrome (DS) and 11 unrelated controls were used for analyzing the effect of
T21. T1DS and T2N denote the T21 and normal twin used. b A reproducible and accurate data-independent acquisition mass spectrometry (DIA-MS) was
used in conjunction with a massively parallel targeted data analysis strategy of SWATH-MS to proﬁle the proteomes. c A dimethylation labeling-based
shotgun proteomics was used to measure protein abundance change in T21 and N sample mixtures. SAX strong anion exchanger. d A pulse SILAC
(pSILAC) experiment determines the protein degradation and turnover rates in T1DS and T2N, respectively, across 6 time points over 24 h
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sample mixtures, strong anion exchanger (SAX) fractionation,
and shotgun proteomics, an alternative proteomic method to
corroborate SWATH-MS results (Fig. 1c; Supplementary Figs. 1,
2).
SWATH-MS provided a near-complete data (proteins quanti-
ﬁed vs. sample) matrix consisting of more than 4000 proteins
across all 56 MS data sets (Supplementary Data 2). This is far
superior to existing DS shotgun proteome data sets, in which only
~65.2% of 4023 IPI protein identities (more redundant than
SwissProt proteins) were measured consistently in three samples
of DS amniocytes15. Moreover, compared to the dimethylation
proteomics workﬂow which quantiﬁed 5636 proteins in the
pooled samples (Supplementary Fig. 2), SWATH-MS of unfrac-
tionated samples covered the majority of proteomic events but
only consumed one-sixth of the instrument time spent per
sample. Importantly SWATH-MS data captured individual
variability by excellent technical and biological reproducibility
in both absolute and relative protein quantiﬁcation. An averaged
Pearson R= 0.985 between all experimental replicates was
achieved for both, 22 unrelated samples and T1DS and T2N.
And an R of 0.780 for T1DS/T2N ratios of all quantiﬁed proteins
was achieved between two independent cell cultures (Supple-
mentary Fig. 3). The data further indicate that the dynamic range
of our method covers over ﬁve orders of magnitude in protein
copy number per cell, ranging from hundreds to tens of millions
copies (Methods; Supplementary Data 1).
The T21 proteome is extensively remodeled. To assess the global
effect of T21 on gene expression at the transcript and protein
level, we correlated transcript (from messenger RNA sequencing
in Letourneau et al.14) and protein concentrations determined in
this study. We found moderate correlations ranging between ρ=
0.339–0.508 in all biological samples, i.e., the twin pair and the
nine matched unrelated pairs of DS/N individuals that were also
published in Letourneau et al.14 (Spearman rank correlation ρ,
Fig. 2a, b; Supplementary Fig. 4). The obtained ρ values are
comparable to those reported previously for mammalian
cells9,22,28. For example, the log-log correlation between the
averaged SWATH intensities and mRNA abundances was 0.509
in T21 state and 0.498 in the normal state in unrelated samples.
While steady-state transcript and protein abundances showed a
moderate level of correlation, transcript and protein DS to N fold
change (FC) correlated weakly: ρ was 0.2114 for unrelated indi-
viduals and merely 0.067 for T1DS/T2N (Fig. 2a, b; Supple-
mentary Fig. 4c). Similar results were obtained from the
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Fig. 2 Global and signiﬁcant post-transcriptional regulations revealed by proteomic data. a Correlation analysis between mRNA abundance and total
protein levels upon T21 revealed a moderate correlation across levels, and weak association regarding cross-layer effects of T21, reﬂected by matching
unrelated samples. b Same analysis to a but in twin samples. c T21 transcript signatures discovered in ﬁbroblast cells of Sullivan et al.5 are conserved
between cell types and impact protein levels. d Volcano plots were generated for twin samples (three aliquots of T1DS vs. three aliquots of T2N), three
pairs of T21, and N samples (unrelated) and the whole unrelated sample set (11 T21 vs. 11 N). Rep1 and Rep2 mean two independent twin cell cultures. Red
circles denote signiﬁcant proteins of >1.5-fold change (FC) at P< 0.05 (Student’s t test). The highlighted yellow circles denote Chr21 proteins
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dimethylation shotgun data (Supplementary Fig. 4c). The
experimental and technical noise in both mRNA and protein
measurements may contribute to an underestimation of true
correlation. However, as the steady-state abundance values and
the calculated FCs were derived from the identical data sets, the
result suggests that substantial post-transcriptional regulation
accounts for the differential impact of T21 observed on the
transcriptome and proteome levels, respectively.
To further investigate the proteomic impact of signiﬁcant
transcriptional events in T21, we overlapped our protein data
with T21 transcript signatures in ﬁbroblast cells described by
Sullivan et al.5 Sullivan et al.5 also analyzed the DS/N
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Fig. 3 Chr21 protein expression and primary dosage compensation. a Correlation analysis between absolute and relative changes between mRNA, protein,
Kdeg for global proteome, proteins encoded by Chr21 and other chromosomes. N.S., not signiﬁcant. b Hierarchically clustered heatmap of FC for mRNA,
protein, and Kdeg. The red and green colors represent “complex_in” and “complex_out” groups, respectively. N.D., not detected. c The dosage
compensation against aneuploidy through protein complex stoichiometry control remained apparent at mRNA, protein, and Kdeg data levels, and is
conﬁrmed by the samples from unrelated individuals. N= 18 and 24 for complex_in and complex_out groups from Ch21 and N= 1906 and 2068 for those
from other chromosomes (Other Chrs). d Binary log2 fold changes (N= 121 comparisons) of Chr21 protein expressions between unrelated individuals. The
red and green colors represent “complex_in” and “complex_out” groups. In all box plots (Methods), the borders represent the 25th and 75th quantile,
respectively, and the bold bar represents the 50th quantile. Wilcox test was used to infer P-values. Standard gene symbols are used, with corresponding
SwissProt IDs listed in Supplementary Data 2
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transcriptomes of other cell types, such as lymphoblastoid cells,
monocytes, and T cells. We found that the signiﬁcantly regulated
transcripts in ﬁbroblast cells are largely conserved between
different cell types, and signiﬁcantly impact the corresponding 69
protein levels (Fig. 2c). However, about 40% of these 69 proteins
are coded on Chr21. Importantly the weak correlations were
obtained between the entire transcriptomes of different cell types
in Sullivan et al.5 and again between transcriptomes and our
quantitative proteomic data (in general R< 0.2, Supplementary
Fig. 5). The data suggest that the transcriptional responses for
nonChr21 genes caused the general low transcript–protein
correlation, which is important to understand the overall T21
phenotype emerged in different cell types.
To evaluate the statistical signiﬁcance of proteome remodeling,
volcano plots were generated for the twin samples (three aliquots
of T1DS and T2N, two independent cell cultures), three pairs of
unrelated T21 and N samples (randomly selected) and the whole
unrelated sample set (11 T21 vs. 11 N). Interestingly, we found a
larger number of upregulated proteins than downregulated
proteins in T1DS compared to T1N (536–537 upregulated
proteins vs. 304–330 downregulated proteins of >1.5 FC at
P< 0.05 (Student’s t-test) from all chromosomes (Fig. 2d). In
both the 3 vs. 3 and 11 vs. 11 comparisons of unrelated samples,
we detected signiﬁcantly smaller numbers of differentially
abundant proteins than the twin samples. We observed that the
unrelated genomes signiﬁcantly buffered the abundance differ-
ences of non-ch21 proteins. These results suggest that the absence
of genomic variability in the twin samples maximizes our ability
to detect small DS/N abundance changes and to thus detect the
roots of phenotypic changes. However, the observed patterns
strictly only apply to the speciﬁc genotype tested. Therefore, our
analyses below attempted to interrogate the consistency of
regulatory events in a population of genetically unrelated DS/N
individuals, in addition to the twins (Supplementary Data 1;
Supplementary Fig. 6).
Gene expression and protein degradation patterns in T21. In a
previous publication in which transcript abundance was com-
pared between T1DS and T2N in the same MZ twin cell system,
Letourneau et al.14 reported gene expression dysregulation
domains (GEDDs) organized by chromosome in DS cells. To
explore the post-transcriptional effects of the presence of an extra
Chr21 in ﬁbroblasts, we used the twin samples and applied
pSILAC21–23 to both T1DS and T2N (three experimental repli-
cates each). Six time points were used for the quantiﬁcation of
protein-speciﬁc degradation rates (Kdeg)21. With the chase dura-
tion over 24 h, about 50% of the total proteome mass was
incorporated by heavy lysine and arginine in all cells (Supple-
mentary Fig. 7). The data from the pSILAC experiments quan-
tiﬁed the Kdeg for 2201 proteins (Fig. 1d; Supplementary Data 3).
Comparing the published transcript data of Letourneau et al.14,
the GEDD patterns reported at the transcript level were not
apparent at the corresponding protein or protein degradation
levels measured in this study (Supplementary Fig. 8). However,
we found that protein turnover was generally faster (shorter
protein half-lives) in T1DS compared to T2N, with 60% of
proteins showing increased Kdeg rates in T1DS. Furthermore, the
absolute T1DS/T2N logFC of Kdeg was on average much smaller
than for mRNA or protein levels (Supplementary Fig. 9). Only
11.2% of the measured degradation rates have FCs above 1.3,
compared to 46.9% of the protein levels and 54.5% of the mRNA
levels (Supplementary Fig. 8). The stability of Kdeg could be
partially explained by the absolute protein abundance per cell and
the haploinsufﬁciency of the gene, i.e., highly abundant and
haploinsufﬁcient proteins tend to be less strongly regulated by
protein degradation rates than other proteins, as expected29
(Supplementary Figs. 10, 11). Altogether, the proteome dynamics
upon T21 demonstrates a similar extent of dysregulation as
compared to transcriptional changes, but seems not to be
organized through the chromosome domains reported at the
transcript level14.
Effects of T21 on Chr21 proteins. We focused on the overall
expression of Chr21 genes, since they are likely to lead the
development of DS phenotypes (Supplementary Fig. 12). In total,
42 Chr21 proteins were quantiﬁed by SWATH-MS and 56 by
dimethylation shotgun proteomics, representing 18.7–24.9% of
the 228 protein coding genes on Chr21, respectively14. In the twin
samples, we found on average FCs for mRNAs, proteins and Kdeg
of 1.38, 1.13, and 1.07, respectively, for Chr21 genes (Supple-
mentary Fig. 8). The correlation between Kdeg and protein FC of
T1DS/T2N was weakly negative for all proteins across the gen-
ome (ρ= −0.051), but was strongly negative for proteins coded on
Chr21 (ρ = −0.416). The signiﬁcant difference between the two
correlations (P= 0.04, z-test) indicates the importance of protein
degradation in shaping Chr21 gene expression in T21 (Fig. 3a).
Next, we analyzed individual Chr21 genes (Fig. 3b). First, we
found that 18 out of 42 mRNAs and 9 out of 42 proteins
displayed a FC> 1.4 in T212. Among these, four genes (GART,
CCT8, HLCS, and HMGN1) were dysregulated both at the
mRNA and protein levels, indicating that they are Chr21 dosage-
sensitive. The upregulation of HMGN1, previously detected at the
transcript level, has been hypothesized to increase chromatin
accessibility and cause transcriptional dysregulation14. The
degradation of HMGN1 in T21 was signiﬁcantly reduced (by
almost 2.5 FC) in our data, supporting the hypothesized need of
upregulating HMGN1 expression in trisomic state14. SOD1,
PFKL, and CSTB proteins showed the largest concentration
increase in T21. They were upregulated by 3.21, 3.01, and 2.02-
fold, respectively. Surprisingly, their corresponding transcripts
were not substantially changed (1.15, 0.96, 1.13 FC, respectively),
indicating a signiﬁcant post-transcriptional upregulation for these
proteins. We also observed the opposite pattern: some proteins
encoded on Chr21 were buffered, i.e., their protein levels
remained close to unchanged, despite substantial upregulation
of their coding transcripts. For example, U2AF1, COL6A1, and
COL6A2 transcript expression increased by 1.18, 1.40, and 1.18-
fold in T1DS/T2N, but were buffered to FC values of 0.87, 0.91,
and 0.85, respectively, at the protein level. Consistently these
three proteins showed the strongest increase in protein turnover
among Chr21-coded ones. Speciﬁcally, Kdeg increased by 1.57,
1.60, and 1.59 FC for U2AF1, COL6A1, and COL6A2 in T21.
Hence, the buffering of protein levels most likely resulted from
adapted protein turnover rather than reduced protein synthesis
rates9,11. To sum up, in response to T21 we discovered non-
uniform expression patterns for Chr21 genes suggesting complex
and varying modes of regulation.
The tight control of protein complex stoichiometry has been
reported as a buffering mechanism against aneuploidy in different
systems10,11,30,31. To analyze the contribution of protein complex
stoichiometry to the T21 phenotype, we classiﬁed proteins into
two groups depending on their inclusion (“complex_in”) or
exclusion (“complex_out”; Methods) from known stable hetero-
meric protein complexes32,33, and compared their log2 FCs.
Transcripts encoding for either, “complex_in” or “complex_out”
proteins from Chr21 (N= 18 and 24, respectively) had similar,
positive FCs (Fig. 3c), which were signiﬁcantly higher than
mRNAs transcribed from other chromosomes (P= 0.00031 and
P= 0.00081, Wilcoxon test—the same test used below). Despite
the similar mRNA level changes, we observed important
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differences between “complex_in” and “complex_out” Chr21
proteins: protein FCs of the “complex_in” group were indis-
tinguishable from “complex_in” proteins on other chromosomes
(P= 0.698). In contrast, the expression of “complex_out” Chr21
proteins in T1DS was signiﬁcantly upregulated compared to other
chromosomes (P= 0.00051). Identical observations were made in
the 22 unrelated samples (Fig. 3c) and were conﬁrmed by
independent dimethylation shotgun proteomics analyzing both
twin and unrelated samples (Supplementary Fig. 13). Our
observations were further conﬁrmed by the protein turnover
measurements: the Kdeg of “complex_in” Chr21 proteins in T1DS
was signiﬁcantly higher than both “complex_out” Chr21 proteins
(P= 0.018) and “complex_in” proteins on other chromosomes (P
= 0.0036). U2AF1, COL6A1, and COL6A2 are typical gene
examples encoding such “complex_in” Chr21 proteins that are
strongly buffered.
Buffering of protein levels against mRNA variation can occur
at multiple scales, including intra- and inter-individual genomic
variation9,34. Therefore, we examined the inter-individual
variability within the unrelated samples, by calculating the
T21/T2N FC for all proteins between all the possible sample
pairs using unrelated samples (i.e., 11 × 11= 121 pairs) and
determined the variability of the protein FC. The 42 Chr21
proteins quantiﬁed in this study demonstrated varied FC and
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quantitative variability among individuals, with HLCS being the
most variable (Fig. 3d). The upregulation of “complex_in”
proteins tended to be less variable among DS individuals than
those of “complex_out” proteins (P= 0.0307, one-tailed χ2-test
based on half-half list splitting), conﬁrming the buffering through
protein complexes discovered from the twin samples. Collectively,
our data indicate that the coordinated protein degradation within
protein complexes is largely responsible for the primary buffering
against excessive transcript and protein dosages due to T21,
which holds true not only within one individual cellular system,
but also between genetically diverse individuals. These important
regulatory effects were not apparent from the transcript data
alone.
Finally, in the twin samples, the Kdeg for both “complex_in”
and “complex_out” proteins encoded on chromosomes other
than Ch21 did not show a difference (P= 0.234, Fig. 3c). Thus,
whereas protein degradation counteracts the gene dosage effect
for proteins encoded on Chr21—especially for members of
protein complexes—we observed concordant regulation of
transcription and protein turnover for proteins encoded on other
chromosomes (see also next sections).
Organelle-speciﬁc protein expression effects of T21. To reveal
the proteomic impact of T21 on cellular functions, we used
reactome pathways33 to connect Chr21-encoded proteins to the
406 proteins with the highest 5% and lowest 5% T1DS/T2N FCs
(Fig. 4). The resulting network signiﬁcantly enriched several
reactome pathways (Supplementary Data 4), such as glycolysis (P
= 2.10e−05; Methods), platelet degranulation (P= 5.44e−06),
integrin cell surface interaction (P= 0.0083), and pentose phos-
phate pathway (P= 0.0044). Strongly overlapping sets of path-
ways were observed as enriched when protein data from the 22
unrelated samples were used (here we selected 406 most strongly
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regulated proteins whose inter-individual CVs were <50% within
the normal group), although the observed FC values were atte-
nuated. The interferon alpha–beta signaling, which was identiﬁed
as a T21 transcriptional signature5, has a marginal P-value of
0.056 at proteome level, perhaps due to the smaller genome
coverage by proteomics. These ﬁndings suggest that common
cellular functions are affected by T21 at the proteome level across
individuals, such as energy metabolism and cell surface signaling
processes.
To extend the analysis of T21 perturbed pathways to the
transcript14 and protein degradation level, we performed gene set
enrichment analysis (GSEA) to identify biological processes that
are consistently associated to high or low FCs at each layer35
(Supplementary Data 5). The intersecting processes between the
protein, transcript, and protein degradation layers denoted
biological functions that were signiﬁcantly and commonly altered
at all three layers. These included cell cycle-related functions, cell
morphogenesis, lipoprotein metabolism, and cellular respiration
in mitochondria (adjusted P< 0.05 at all layers, Fig. 5a;
Supplementary Fig. 14). There is a remarkably reciprocal
regulatory pattern between mRNA and protein turnover. For
example, proteins related to the cell cycle and morphogenesis are
transcriptionally induced in T21 and have lower Kdeg, whereas
proteins responsible for cellular respiration process are tran-
scriptionally tuned down and have higher Kdeg. This reciprocal
pattern suggests a concordant regulation of these protein levels
through synthesis and turnover (Fig. 5a).
To systematically characterize proteome-wide protein degrada-
tion in T21, we divided the protein list based on Kdeg FC of T1DS/
T2N into ﬁve even sets (quintiles), and asked which GO biological
processes were enriched in each quintile (Fig. 5b). For example
the quintile with the highest Kdeg in T1DS (labeled as +++) was
enriched for lipid metabolic process (P= 0.00136), exocytosis
(P= 0.0037), mitochondrion organization (P= 0.0085), and
protein transport (P= 0.0099) (Fig. 5c; Supplementary Data 6).
Similarly distinctive patterns were observed for other quintiles.
These enriched GO biological processes signiﬁcantly associate to
different cellular components/compartments. We therefore per-
formed the same enrichment analysis based on GO cellular
component annotations. Different organelles and cellular com-
ponents are strikingly, and in most cases uniquely, enriched based
on the extent of protein degradation regulation in T21 (Fig. 5d;
Supplementary Data 7). Speciﬁcally, those genes that have the
highest Kdeg rates in T1DS are drastically enriched for
mitochondrial genes (+++: P= 1.52e−8; ++: P= 0.0074). Lyso-
some genes were uniquely enriched among the ones with the
highest Kdeg (+++; P= 0.014), while cytosolic ribosome genes
have slightly elevated Kdeg (++; P= 4.60e−17; +; P= 5.18e−15).
Other gene categories had relatively unchanged Kdeg, such as
cytosol (+; P= 1.36e−7), spliceosome (+; P= 0.0267), proteasome
complex (−; P= 1.58e−4), and chromosome (−; P= 0.036).
Remarkably, the turnover of plasma membrane (−−;
P= 3.02e–4) and cell surface (−−; P= 0.0166) related proteins
were greatly slowed down in T21. In summary, our data strongly
indicate that an extra copy of Chr21 triggers an organelle-
dependent and coarse-grained protein degradation gradient in
ﬁbroblasts.
Next we explored the organelle-speciﬁc gene expression control
in T21 (Fig. 5e). We estimated steady-state protein synthesis rates
(Ksyn) (Methods). First, we found that Ksyn globally recapitulates
the protein level regulation. Thus, protein degradation generally
ﬁne-tunes protein levels after synthesis in most organelles.
Second, we discovered that in mitochondria, peroxisomes, and
lysosomes, protein degradation prominently buffered against
mRNA variation to shape the protein levels. The dimethylation
proteomic data showed consistent patterns of organelle regulation
at the protein level (Supplementary Fig. 15a). Third, T21 turned
out to have a limited effect on nucleolar gene expression. Fourth,
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although ribosome-related transcripts were suppressed and
ribosomal protein degradation accelerated, the cytosolic riboso-
mal proteins were clearly upregulated in T21 cells, strongly
suggesting that the translation rate of ribosome-related genes was
massively increased, an observation for which the transcriptomic
data alone may lead to contradictory conclusion5. Finally, we
used a recently published subcellular map of the human
proteome, derived from antibody-based microscopy experiments,
as an alternative annotation system of organelles36, and obtained
identical patterns as the results showed in Fig. 5d (Supplementary
Fig. 16). Altogether, our multilayered data essentially dissected
gene regulation in each organelle under the aneuploidic stress of
T21.
Our integrative data of T1DS and T2N permits systems-level
accounting of absolute proteomic cost for cells and relative cost
when they bear an extra Chr21. We therefore calculated the
proteome investment (copies per cell times protein molecular
weight (MW)) and synthesis expenses for different organelles
(Fig. 5f). We found that cytosolic proteins, despite comprising
~23% of the total quantiﬁed proteome, consumed only about 10%
of the total synthesis expense in T1DS and T2N cells, indicating
that these proteins have a generally slow turnover. In contrast, the
peroxisome constitutes only 0.88% of the quantiﬁed proteome,
but these proteins represent 6.6% of the absolute protein copies in
T1DS and T2N samples. Meanwhile, their synthesis expense is of
much lower percentage (~1.75%), indicating slow Kdeg. The
opposite pattern is observed for the Golgi-related proteins.
Interestingly, when T2N and T1DS are compared, we found that
protein investment and synthesis rate and expense are all smaller
in T21 cells for proteins of the extracellular space and plasma
membrane. Again, the opposite pattern is observed for cytosolic
proteins and ribosome proteins, suggesting that T21 cells seem to
invest more on inside the cells than on the cell surface.
The manifestation of Chr21-induced organelle aberrations
discovered above from twin samples is modulated by genomic
differences and/or environmental factors in the genetically
different DS cases tested. Whereas the overall correlation of
T21/T2N FC for all the quantiﬁed proteins between twin and
unrelated sample sets is modest (R= 0.200–0.279, Supplementary
Fig. 15b, c), we observed a signiﬁcant consistency of organelle
proteome aberrations between twins and unrelated samples, when
the individual variations are averaged by sample mixing and
dimethylation based quantiﬁcation (R= 0.78; Fig. 6a). Moreover,
we found that the absolute FCs of organelle proteomes were
typically smaller in the unrelated individuals compared to the
twins using individual SWATH-MS data sets (Fig. 6b–d). Speciﬁc
cellular components such as lysosome and cell surface proteins
showed high variability in regulatory trends between unrelated
DS individuals (Fig. 6; Supplementary Fig. 17). Thus, we deduce
those organelle-based functions that are consistently regulated
between unrelated individuals, such as cell cycle regulation,
ribosome translation, and mitochondrial respiration (Fig. 5a),
likely drive several cellular hallmarks of DS phenotypes.
Conversely, the most variable organelles, such as lysosome
exocytosis and cell–cell surface signaling, may contribute to the
variability of DS phenotypes.
Co-regulation of mitochondrial protein complexes. Mitochon-
drial downregulation emerges as one of the most signiﬁcant DS
phenotypes, which was conﬁrmed in both discordant twins and
unrelated individuals (Fig. 6c). Speciﬁcally, we quantiﬁed 33, 3, 5,
7, and 12 proteins from the mitochondrial respiratory complexes
I–V, respectively, and among these we quantiﬁed the Kdeg
changes for 22, 2, 4, 6, and 11 proteins in T1DS and T2N. For
these genes, 49 out of 60 (81.6%) transcripts are downregulated in
T21. Remarkably, all of 60 genes (100%) are downregulated at the
protein level in T1DS with an average FC of 1.39, which can be
partially ascribed to the fact that 84% of these proteins increased
their Kdeg by an average of 11.2% (Fig. 7). Also, 53 out of 60
proteins (88.3%) are downregulated in unrelated DS based on
their averaged FC. The uniform downregulation of mitochondrial
respiration complexes was veriﬁed by Western blotting analy-
sis (Fig. 7; Supplementary Fig. 18). Among these complexes,
complex V (ATP synthase) is of particular interest, because it
includes two identiﬁed Chr21 proteins, ATP5J and ATP5O.
Although we observed increased transcript levels of ATP5J and
ATP5O due to T21, protein levels were clearly below normal.
Altogether, our data provide evidence for a strong repression of
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respiratory chain complexes due to T21, which is consistent with
prior work37,38.
Discussion
Due to the previous technical limitations of proteomics, the
impact of Chr21 gene expression on DS phenotypes thus far has
been based on (i) the established functions of Chr21 proteins
from individual biochemical studies, and (ii) the dosage measured
at the transcript level in DS samples2,39. Such studies may,
however, be inadequate due to the existence and complexity of
post-transcriptional regulation in mammalian systems9,22,23. To
understand molecular mechanisms perturbed by T21 in more
depth to potentially identify actionable therapeutic targets, it is
essential to probe the gene dosage imbalance in DS at the protein
level. Indeed, we found that the correlation between the pre-
viously reported mRNA and our protein FC upon the gain of the
extra Chr21 was weak (Fig. 2a, b), demonstrating the importance
of studying the entire proteome. To date, proteome-wide abun-
dance and turnover measurements have been lacking for
T21 cells, indicating our data set itself a signiﬁcance resource for
DS research. For example, the dosage-sensitive proteins escaping
the protein level buffering mechanisms discovered by our study
could be more relevant to DS development and phenotypes.
Compared to previous studies, which only measured a few pro-
teins in clinical DS samples16,17, in the present study several state-
of-the-art proteomic methods including SWATH-MS, absolute
label-free quantiﬁcation (aLFQ), and pSILAC were jointly
applied. SWATH-MS quantiﬁcation is based on multiple frag-
ment ion chromatograms per quantiﬁed peptide and has been
shown to provide selectivity and accuracy comparable to selected
reaction monitoring (SRM) measurement18,19, the gold standard
quantitative mass spectrometric method. Further, SWATH-MS
has shown lower limit of detection than MS1-based proﬁling
under comparable experimental conditions18,40. Our SWATH-
MS-based label-free quantiﬁcation achieved sufﬁcient accuracy
and desired statistical signiﬁcance in this study. Collectively, the
techniques used have broken through a major technical hurdle of
studying the effects of T21 on the proteome.
In this study, we used ﬁbroblast cells for reasons of easy
accessibility as proxies to understand the impact of T21 on basic
cellular processes in DS. There are at least three phenotypes of DS
potentially reﬂected by ﬁbroblast cells (See Supplementary
Table 1 for literature summary): (a) endosome pathology related
to Alzheimer;4,41 (b) apoptotic phenotype;42 (c) Higher oxidative
stress related to premature ageing. Recently, the transcriptional
activation of the interferon response pathway due to T21 was also
ﬁrst discovered in ﬁbroblast5. Nevertheless, the use of ﬁbroblast
may limit the impact of certain ﬁndings present and the study of
other cell types and tissues will be necessary to fully understand
the speciﬁc effects and other phenotypes of T21.
In DS, the observed (molecular) phenotypes are the result of
genomic variability between individuals and the third copy of
Chr21. The combination of the twins and unrelated samples
provides a unique perspective for understanding the speciﬁc
consequences of T21, and permits the calculation of inter-
individual variability both exclusively within Chr21 and across
the rest of the genome. It was reported that frequently genetic
variance affecting protein abundance has no effect on mRNA
levels34,43. Our study conﬁrmed this extra dimension of com-
plexity at the proteomic level. HLCS, a Chr21 protein that par-
ticipates in chromatin condensation and gene repression14,44, was
dosage-sensitive in both twin and unrelated samples, but showed
highest quantitative variability among DS individuals (Fig. 4a).
Other variable consequences of T21 are largely caused by geno-
mic variation outside Chr21. For example, for proteins of the
class “cell-cell surface signaling” we found considerable variability
between unrelated individuals, suggesting that their abundance is
affected by genomic and environmental variation. Additionally,
proteins in the lysosome and endoplasmic reticulum groups also
exhibit large inter-individual variation, likely contributing to the
biological variation between DS individuals.
We observed a variable, organelle-dependent protein degra-
dation extent resulting from T21. Previously the cellular
compartment-speciﬁc differences in Kdeg had been observed in a
steady-state system by blocking the proteasome45. Also, the
mitochondrial and cell surface signaling alterations have been
previously observed at the transcript level in DS46. Whether these
organellar abberrations (Fig. 3) are speciﬁc for T21 or occur in
response to any genome gain aneuploidy remains to be
discovered.
Previous studies have investigated the proteomes of different
aneuploidy systems in yeast11, ﬂy30, human cancer cells10, and in
artiﬁcial microcell fusion-induced human cells carrying different
additional chromosomes7,31. Here we quantiﬁed both protein and
protein degradation in a unique cohort of T21 primary cells to
study the impact of T21 aneuploidy. Our data indicate a mild but
global acceleration of protein turnover in T21 cells. Further, we
found that those Chr21 proteins that are members of heteromeric
protein complexes were less affected by the increased gene dosage
due to aneuploidy, a buffering effect that is mediated by accel-
erated protein degradation. Although tight stoichiometric control
of protein complex subunits was previously reported as a buf-
fering mechanism in aneuploidy10,11,30,31, no studies have yet
directly quantiﬁed the regulation of Chr21-wide protein turnover
or in clinically derived samples. It has been a long-standing
hypothesis that proteins are stabilized by complex formation and
by protein degradation against misfolded proteins47. The concept
has been investigated with many individual studies as reviewed
recently9. We argue that by generating sample-speciﬁc protein
complex data sets (e.g., by size-exclusion chromatography48), our
ﬁnding can be further extended and its signiﬁcance generalized.
Furthermore, previous studies have debated the extent (or even
existence) of dosage compensation in eukaryotic cells49,50. Our
data show that—at least in T21—protein dosage compensation
exists and plays a primary role in the mechanistic processes
underlying DS.
Altogether, our data distinguish two classes of proteins. The
ﬁrst class consists of proteins for which it is apparently necessary
for the cell to regulate the abundance in order to cope with the
stress induced by the extra Chr21. Examples of this class are
instances with consistently upregulated mRNA and protein levels
at reduced Kdeg, as well as instances with consistently reduced
protein expression (Fig. 5a). The second class contains cases for
which altered mRNA abundance levels are buffered at the protein
level, i.e., where the protein FC is smaller than RNA FC. In some
cases this is achieved by an increased Kdeg. We discovered that the
second class is particularly prominent on Chr21 (Figs. 2c, 3c),
because the cell cannot change the copy number state. Responses
of proteins on other chromosomes might be a mix of both classes.
Finally, our data clearly demonstrate that the mitochondrial
proteins in the ﬁve ETC complexes are signiﬁcantly and uni-
formly downregulated in T21. Using astrocytes and neuronal
cultures from DS fetuses, Busciglio et al.51 showed in 2002 that
altered metabolism of the amyloid precursor protein (APP) and
oxidative stress result from mitochondrial dysfunction. The
transcriptional and functional analyses have showed that the
reduced mitochondrial activity in DS acts as an adaptive response
for avoiding injury and preserving basic cellular functions in
DS37. Moreover, the mitochondrial alteration affecting reactive
oxygen species homeostasis was suggested to lead the pathogen-
esis of various neurodevelopmental syndromes including DS38.
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Recently genes implicated in energy metabolism, mitochondrial
activity, and biogenesis are reported to be downregulated in the
Ts3Yah mice, which carry a duplication syntenic to human
21q11.2-q21.352. In our results, the dysfunctional mitochondria
were apparent at both protein and protein degradation levels,
signiﬁcantly reinforcing the previous observations. Such knowl-
edge may pave novel avenues for DS therapeutics, e.g., by acti-
vating mitochondrial function, reducing oxidative stress, and thus
ameliorating the physiological DS symptoms. As promising
examples, novel translational approaches involving the utilization
of coenzyme Q10 (CoQ10) were used to treat a variety of clinical
phenotypes associated with DS53. Also, the use of metformin was
recently found to be effective to reverse mitochondrial dysfunc-
tion in DS cells, thus exerting protective effects against DS-
associated pathologies54.
In summary, we expect that this proteome and proteostasis
proﬁling data set illustrates the signiﬁcance of proteome level
dosage analysis for genetic diseases like human DS and will
beneﬁt future studies.
Methods
Samples and cell culture. The forearm primary fetal skin ﬁbroblasts were col-
lected post mortem from the T1DS and T2N discordant twins at 16 fetal weeks,
after IRB approval from the Ethical Committee of University Hospitals of Geneva,
and written informed consent by both parents14. Two vials of cells were thawed
and cultured separately; the two cultures represent the two biological replicates.
Next, biological replicates were divided into three cultures and handled as technical
replicates. To compare and generalize our ﬁnding, we also analyzed two technical
replicates of unrelated primary skin ﬁbroblasts from 11 DS individuals and 11
unaffected individuals (Supplementary Data 1). The written informed consent was
obtained from all human participants in this study4. All primary ﬁbroblasts were
grown in DMEM with GlutaMAX (Invitrogen, Life Technologies) supplemented
with 10% fetal bovine serum (Life Technologies) and 1% penicillin/streptomycin/
fungizone mix (Amimed, BioConcept) in a 37 °C incubator supplied with 5% CO2.
Pulsed SILAC experiment. For the pSILAC experiment, SILAC DMEM High
Glucose Medium (GE Healthcare) lacking L-arginine, L-lysine was supplemented
with either light or heavy isotopically labeled lysine and arginine, 10% dialyzed fetal
bovine serum (PAN Biotech), and 1% penicillin/streptomycin mix (Gibco). Spe-
ciﬁcally, 146 mg per liter of heavy L-lysine (13C615N2) and 84 mg per liter of
arginine (13C615N4) (Chemie Brunschwig AG) and the same amount of corre-
sponding non-labeled amino acids (Sigma-Aldrich)22 were supplemented, respec-
tively, to conﬁgure heavy and light SILAC medium. Additionally 400 mg per liter L-
proline (Sigma-Aldrich) were also added into SILAC medium to prevent the
potential arginine–proline conversion. The three replicates of T1DS and T2N
samples were used. The identical ﬁbroblast cell aliquots were ﬁrst split and grown
in the light SILAC medium. At time point zero (t0= 0 h), the medium were
switched into heavy SILAC medium upon the gentle washing of three times by pre-
warmed PBS, and totally six time points were included (0, 1, 4, 8, 14, and 24 h) to
conﬁgure the pSILAC course. At each time point, the cells were collected as snap
frozen pellets after three times of pre-cold PBS washing. The cell pellets were stored
in −80 °C for proteomic analysis.
Cell doubling time determination. The cell doubling time T1DS and T2N was
carefully conducted by triplicate cell counting at nine time points (0, 7, 24, 31, 48,
55, 72, 79, and 96 h) on a hemocytometer. Three independent experiments were
conducted in three technical replicates. The average doubling times for T1DS and
T2N were determined to be 48.4 and 43.3 h, respectively (P= 0.049, Student’s t
test). The formula used to calculate the doubling time is: Duration × log(2)/log
(FCN)−log(ICN) where Duration= duration of the cell growth, FCN= the ﬁnal
number of cells at end of a given time point, ICN= the initial number of cells at
time point 0 h, i.e., inoculum.
Protein extraction and in-solution digestion. The cell pellets were suspended in
10M Urea lysis buffer and complete protease inhibitor cocktail (Roche), ultra-
sonically lysed by sonication at 4 °C for 2 min using a VialTweeter device (Hiel-
scher-Ultrasound Technology), and then centrifuged at 18,000×g for 1 h to remove
the insoluble material. The supernatant protein mixtures were reduced by 10 mM
tris-(2-carboxyethyl)-phosphine (TCEP) for 1 h at 37 °C and 20 mM iodoaceta-
mide (IAA) in the dark for 45 min at room temperature. All the samples were
further diluted by 1:6 (v/v) with 100 mM NH4HCO3 and digested with sequencing-
grade porcine trypsin (Promega) at a protease/protein ratio of 1:25 overnight at 37
°C. The amount of the puriﬁed peptides was determined using Nanodrop ND-1000
(Thermo Scientiﬁc) and 1 μg peptides was injected in each LC-MS run.
Shotgun proteomics on triple TOF. The peptides digested from cell lysate derived
from normal cell culture and lysate and the samples of the pSILAC experiment
were measured on an SCIEX 5600 TripleTOF mass spectrometer operated in DDA
mode18. An Eksigent NanoLC Ultra 2D Plus HPLC system and a 20 cm PicoFrit
emitter (New Objective, self-packed to 20 cm with Magic C18 AQ 3 μm 200 Å
material) were used for peptide separation. For the HPLC method, the buffer A
used was 0.1% (v/v) formic acid, 2% (v/v) acetonitrile, whereas the buffer B was
0.1% (v/v) formic acid, 98% (v/v) acetonitrile. We adopted a 120 min gradient of
2–35% buffer B with a ﬂow rate of 300 nL/min. For MS method, a survey scan at
the MS1 level (360–1460m/z) was ﬁrst carried out with 500 ms per scan. Then, the
shotgun settings were designed to sequence the Top20 most intense precursors,
whose charge states are 2–5. Signals exceeding 250 counts per second were selected
for fragmentation and MS2 spectra generation. MS2 spectra were collected in the
mass range 50–2000m/z for 100 ms per scan. The dynamic exclusion parameters
were set so that already sequenced precursor ions were excluded from reselection
for 20 s duration.
Shotgun proteomics on Orbitrap Elite. The pSILAC samples were also measured
on Oribtrap Elite (Thermo Scientiﬁc) for comparison between the conventional
method and the SWATH-MS-pSILAC pipeline. Brieﬂy, 1 μg of peptide sample was
injected per run and a Thermo Easy-nLC 1000 HPLC system with a 15 cm long
PepMap column (particle size 2 μm, Thermo Scientiﬁc) was used for peptide
separation. The LC gradient was set to be 3 h from 5% B to 30% B. The ﬂow rate
was 300 nl/min. Buffer A was composed of 2% acetonitrile, 0.1% formic acid in
water; and buffer B was 2% water, 0.1% formic acid in acetonitrile.
In the MS method, MS2 spectra were acquired in the ion trap using CID mode.
The normalized collision energy (CE) was set to be 35%. The Top 15-method was
used, which means that the most abundant 15 precursors per cycle were selected
for MS/MS analysis. We used the following resolution settings: MS1 recorded at
120,000 and MS2 recorded at normal resolution for trap-CID. Those MS1 signals
of charge state +1 and those of unknown charge state were excluded from
fragmentation and MS2 data generation. Precursor isolation width was 2m/z.
MS1 scans were set to a maximum of 1,000,000 counts and a maximum ﬁll time of
200 ms. MS2 trap scans were set to a maximum of 10,000 counts and a maximum
ﬁll time of 100 ms. The dynamic exclusion parameters were set so that already
sequenced precursors were excluded from reselection for 30 s.
Following measurement, the Elite data in.raw format was analyzed by
Maxquant55 and searched against human Swissprot database (downloaded April
2015) following standard SILAC settings. Specially, peptide tolerances at MS and
MS/MS level were set to be 4.5 ppm and 0.75 Da, respectively. Up to two miss
cleavages were allowed. Oxidation at methionine was set as a variable modiﬁcation,
whereas carbamidomethylation at cysteine was set as a ﬁxed modiﬁcation. To avoid
incorrect identiﬁcations (especially for heavy channel) at early time points, the
requantiﬁcation and “match between runs” options were disabled. Other
parameters are kept as default in Maxquant55. Both peptide- and protein-level
results were controlled at 1% FDR56.
SWATH mass spectrometry. Steady proteome and pSILAC samples were both
measured by SWATH-MS. The same LC-MS/MS systems used for DDA mea-
surements on SCIEX 5600 TripleTOF was also used for SWATH analysis18,19. For
pSILAC samples, a 90-min LC gradient was used. For the MS method, we used a
selection scheme of 64 variable wide precursor ion windows in the quadrupole.
These windows were set to be at the ranges of 399.5–408.2, 407.2–415.8,
414.8–422.7, 421.7–429.7, 428.7–437.3, 436.3–444.8, 443.8–451.7, 450.7–458.7,
457.7–466.7, 465.7–473.4, 472.4–478.3, 477.3–485.4, 484.4–491.2, 490.2–497.7,
496.7–504.3, 503.3–511.2, 510.2–518.2, 517.2–525.3, 524.3–533.3, 532.3–540.3,
539.3–546.8, 545.8–554.5, 553.5–561.8, 560.8–568.3, 567.3–575.7, 574.7–582.3,
581.3–588.8, 587.8–595.8, 594.8–601.8, 600.8–608.9, 607.9–616.9, 615.9–624.8,
623.8–632.2, 631.2–640.8, 639.8–647.9, 646.9–654.8, 653.8–661.5, 660.5–670.3,
669.3–678.8, 677.8–687.8, 686.8–696.9, 695.9–706.9, 705.9–715.9, 714.9–726.2,
725.2–737.4, 736.4–746.6, 745.6–757.5, 756.5–767.9, 766.9–779.5, 778.5–792.9,
791.9–807, 806–820, 819–834.2, 833.2–849.4, 848.4–866, 865–884.4, 883.4–899.9,
898.9–919, 918–942.1, 941.1–971.6, 970.6–1006, 1005–1053, 1052–1110.6,
1109.6–1200.5. The MS2 acquisition mass range was set to be 50–2000m/z. For
each window, optimized CE was applied. This was based on the calculation for a
charge 2+ ion centered in the particular window, but with a spread of 15 eV. The
dwell time was set to be 50 ms for all fragment ion scans (MS/MS scans) in “high-
sensitivity” mode. In this way, a duty cycle was ~3.45 s consisting of a survey scan
(high-resolution mode) of 250 ms and 64 fragment ion scans of 50 ms, respectively.
SWATH-MS data analysis on protein expression. For analyzing the steady-state
proteomes of twin samples and unrelated samples, the SWATH-MS identiﬁcation
was performed by OpenSWATH software24 searching against a previously estab-
lished SWATH assay library, which contains mass spectrometric assays for 10,000
human proteins26. OpenSWATH ﬁrst identiﬁed the peak groups from all indivi-
dual SWATH maps at a target FDR= 1% (at least one run with q-value below
0.0236% for any given peak group) and then aligned between SWATH maps with
extension FDR= 5% using a TRIC (transfer of identiﬁcation conﬁdence) algorithm
that was speciﬁcally developed for targeted proteomic data analysis25. The
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requantiﬁcation feature in OpenSWATH was enabled, but only those peptide
groups identiﬁed in more than 33% of the samples were proceeded for requanti-
ﬁcation. As discussed previously, protein FDR needs speciﬁc attention when the
large, external spectral libraries are used in targeted proteomics26. Therefore, to
pursue a strict quality control of protein-level identiﬁcation, we further utilized
Mayu software27, which computed and applied an m_score cutoff of
0.00000218972 at the peptide peak group level to achieve the protein FDR of 1% in
our ﬁnal result. Using an in-house script, the signal normalization step by local
intensity sums in retention time space57 was performed at peptide level before
summarizing protein intensities. To quantify the protein abundance levels across
samples, we summed up the most abundant peptides for each protein (i.e., top
three peptide groups based on intensity were used for those proteins identiﬁed with
more than three proteotypic peptide signals, whereas all the peptides were sum-
marized for other proteins). This allows for reliably estimating global protein level
changes as shown in previous studies58,59. The protein expression data matrix was
quantile normalized and log2 transformed for statistical and bioinformatics
analysis.
SWATH-MS data analysis on pSILAC data. To analyze SWATH results of
pSILAC experiment, we ﬁrst generated a sample-speciﬁc library containing the
light and heavy peptide assays. All the shotgun runs of the “Light” samples (those
from steady proteome as well as t0 samples in pSILAC experiment) were ﬁrst
searched against human SwissProt database using the iPortal pipeline60. Proﬁle-
mode.wiff ﬁles from shotgun data acquisition were centroided and converted to
mzML format using the AB Sciex Data Converter v.1.3 and converted to mzXML
format using MSConvert v.3.04.238. iPortal utilized iProphet schema61 to integrate
the search results from X!Tandem, Omessa, Myrimatch, and Comet at peptide level
FDR= 1%. Xinteract option was “-dDECOY_ -OAPdlIw”. Especially, peptide
tolerances at MS and MS/MS level were set to be 75 ppm and 0.1 Da, respectively.
Up to two missing trypsin cleavages were allowed. Oxidation at methionine was set
as variable modiﬁcation, whereas carbamidomethylation at cysteine was set as ﬁxed
modiﬁcation. The light version of the raw spectral library was generated from all
valid peptide spectrum matches and then reﬁned into the non-redundant con-
sensus libraries using SpectraST62. Using the spectrast2tsv.py function in Open-
SWATH24, we then generated both the light and heavy MS assays as the ﬁnal
library constructed from top 3–6 most intense fragments with Q3 range from 400
to 1200m/z excluding those falling in the precursor SWATH window were used for
targeted data analysis of SWATH maps. The ﬁnal library contained 41,386 peptide
sequences of 4111 unique SwissProt proteins. OpenSWATH analysis was run with
the same options as above for protein expression data, however, as the shotgun
proteomic analysis, requantiﬁed data points were discarded for protein turnover
calculation.
Dimethylation shotgun proteomics. The dimethylation experiment was con-
ducted with the purpose to conﬁrm the SWATH-MS results based on a pooling
strategy, SAX fractionation63, the following up shotgun measurement, and data
analysis using Maxquant55. All reagents were purchased from Sigma-Aldrich
(USA).
Dimethylation labeling based on “light” and “intermediate” channels was
conducted following the in-solution labeling protocol64. Peptide digests from the
three technical replicates (8 μg each) derived from both biological replicates T1DS
and T2N twin samples were mixed and labeled with CH2O or CD2O. The
biological replicates were pooled again, respectively, for following SAX
fractionation. The peptide digests from the two biological replicates of 11 unrelated
healthy individuals and 11 DS cases (2 μg each) were also pooled, respectively,
before dimethylation labeling reaction. Peptides labeled were ﬁrst lyophilized,
dissolved in ddH2O, and adjusted to pH 11 by adding 1 M NaOH before SAX
fractionation.
Then, 50 µg of peptide mixtures (of twin samples and unrelated samples) were
then separated into six fractions by SAX63. Totally six pH steps (11, 8, 6, 5, 4, 3,
using buffer composed of 20 mM acetic acid, 20 mM phosphoric acid, and 20 mM
boric acid titrated with NaOH to the desired pH) were applied and results in six
SAX fractionations for further shotgun proteomic analysis.
The dimethylation peptide samples were measured on an EASY-nLC 1000
(Thermo Fisher) coupled to a Q Exactive Plus mass spectrometer (Thermo Fisher).
Peptides were separated on a column (40 cm × 0.75 µm), packed in-house with
reversed-phase ReproSil-Pur C18-AQ resin (1.9 µm, Dr. Maisch). Peptides were
eluted for 80 min using a segmented linear gradient of 5–40% solvent B (99.9%
acetonitrile, 0.1% formic acid) at a ﬂow rate of 300 nl/min. Survey full-scan mass
spectra were acquired with mass range 350–1500m/z, at a resolution of 70,000 at
200m/z and the 20 most intense ions above an intensity of 7.3e4 were sequentially
isolated, fragmented (HCD at 35 eV) and measured at a resolution of 17,500 at 200
m/z. Peptides with a charge of +1 or with unassigned charge state were excluded
from fragmentation for MS2, and a dynamic exclusion of 30 s was applied. Ions
were accumulated to a target value of 3e6 for MS1 and of 2e5 for MS2.
The raw ﬁles were searched against human SwissProt database using Maxquant.
The “DimthLys0” and “DimethNter0” labels were enabled for the light labels and
the “DimethLys4” and “DimethNter4” were enabled for heavy labels. Oxidation at
methionine was set as variable modiﬁcation, whereas carbamidomethylation at
cysteine was set as the ﬁxed modiﬁcation. Up to two missed cleavages were allowed.
The peptide tolerances were set as 6 and 20 ppm at MS and MS/MS levels. The
feature of “match between runs” and requantiﬁcation were enabled with a match
window of 0.7 min. Other parameters are kept as Default in Maxquant55. Both
peptide- and protein-level results were accepted at 1% FDR.
Speciﬁcally, to test the labeling efﬁciency, the “DimthLys0” and “DimethNter0”
labels and the “DimethLys4” and “DimethNter4” labels were, respectively, set as
variable modiﬁcations for the “light” and “Intermediate” samples. Accordingly, we
determined the labeling efﬁciency is 99.66 and 99.86% for the “light” and “heavy”
channels based on the numbers of total peptides modiﬁed by dimethylation labels
or not. Further among the peptides ending with lysine, 99.84 and 99.90% of them
were dimethyl labeled at both peptide N terminus and the side chain of lysine
residues. The data suggested the dimethyl labeling was completed in this
experiment.
Determination of protein turnover rate. In pSILAC, the turnover behavior of
heavy and light signals of different proteins thus permits the quantiﬁcation of
protein-speciﬁc degradation rates (Kdeg). The rates of loss of the light isotope (kloss)
were directly calculated from the output data matrix generated by OpenSWATH.
We modeled the relative isotope abundance (RIA)21, deﬁned as the signal intensity
in the light channel divided by the sum of light and heavy intensities, onto an
exponential decay model assuming a null heavy intensity (RIA= 1) at time 0, i.e.,
RIA tð Þ ¼ e Kloss ´ tð Þ: ð1Þ
The ﬁt was obtained through nonlinear least-squares estimation (“nls” function
in R, with a starting Kloss parameter of 0.1).
To calculate protein level Kloss, when several peptides were available for a
protein we ﬁrst excluded peptides whose signal was absent in some of the samples.
When more than four peptides were available for a certain protein, we excluded
outliers (deﬁned as having a probability <10e−4 in the empirical distribution of
median Kloss of the peptides of that protein). We then performed a weighted
average of the kloss value of each peptides of the protein, using as weights the
number of data points available for the peptide divided by the variance of peptide’s
kloss estimate (obtained from the model’s ﬁt), which ensured giving more weight to
peptides carrying robust information. Importantly, this method maximized
correlation and minimized median absolute error across replicates.
Next the ﬁnal protein degradation rate Kdeg was calculated by the equations21,22:
Kdeg ¼ Kloss  Kdil ð2Þ
Kdil ¼ ln 2ð Þ=tcc; ð3Þ
where Kdil is the dilution rate due to the cell doubling and tcc denotes the cell
doubling time (which differs between T1DS and T2N).
Absolute label-free quantiﬁcation. The practice of aLFQ was used20. In the
present study, to derive absolute protein abundance estimates, 34 anchor proteins
covering a wide abundance range in human proteome were targeted by manual
data extraction using Skyline65. A total of 42 heavy reference peptides with known
amount were spiked into a representative T1DS and a T2N sample to determine
the endogenous levels of peptides digested from the samples, by absolute quanti-
ﬁcation (AQUA)66. The manual inspection of the light and heavy peaks using
Skyline excluded low intensity and low-quality peak groups and also exclude the
light-to-heavy ratios below 0.04 or above 25, resulting in reliable quantiﬁcation of
20 ﬁnal anchor proteins by 20 AQUA peptides. In this way, the absolute moles of
these anchor proteins were obtained.
In the next step, we averaged the total protein concentrations quantiﬁed by Bio-
Rad assay from the same amount of cells (1 million) of all the ﬁbroblast samples
(regardless of T1DS or T2N, or unrelated cases). This averaged constant links the
number of cells being digested to the micrograms of total proteins (i.e., it provides a
general total protein concentration per cell). Thus, for those ﬁnal anchor proteins
whose absolute moles were already quantiﬁed (per 1 μg protein digest injected into
LC-MS), we estimated the copies per cell numbers for all the anchor proteins. Next,
based on the log-log correlation (Supplementary Fig. 10) between the SWATH-MS
intensities (from protein expression data of one T1DS and T2N sample) and the
copies per cell values for all the anchor proteins, we generated the linear equation
for T1DS and T2N status separately. Finally, the copies per cell values (absolute
amounts) of all the proteins in the proteome quantiﬁed in “protein expression
analysis” can be determined using the respective log-log linear equation and their
measured SWATH-MS intensities in T1DS and T2N.
In the above approach, we did not apply the aLFQ model selection67 and we
performed the AQUA only based on single-point ratios (see above) rather than
dilution curves. Although the estimation accuracy of absolute protein
concentration per cell might be lower than the previous studies which optimized
these steps20,67, our simple approach here essentially provided the copies per cell
estimate for all the proteins (including those quantiﬁed with only one peptide), and
enabled the proteome-wide investment comparison between T1DS and T2N.
Another consideration is the possible deviation of the protein amount per cell
estimation due to the variations during protein extraction, concentration
determination, and peptide digestion. However, such a deviation is unlikely to
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impair the present study as parallel protein extraction and digestion was performed
between samples.
Estimating protein synthesis expense and proteome investment. We deter-
mine the protein synthesis rate based on following equations and reasoning29,68.
For a state in equilibrium, the relationship between the rate constants for synthetic
and degradative reactions are can be described as
dPx=dt ¼ Ksyn þ P ´ e Kdeg ´ tð Þ; ð4Þ
where dPx/dt denotes the change of protein amount in time, and Px(t) is the
absolute amount of the protein x at time t, which is estimated by the aLFQ in the
present study.
At a steady state, dPx/dt= 0. Therefore,
Ksyn¼ Px tð ÞKdeg ð5Þ
i.e., in a given cell, Ksyn= protein copies (i.e., quantile normalized copies for
generating Fig. 5f) times Kdeg.
We further estimated the protein investment for each protein69. The total mass
of a particular protein was calculated by multiplying number of instances of the
protein (i.e., protein absolute quantities) by the mass of the individual proteins (i.e.,
protein MW) was used as a reference for the cost associated to the production of
each protein. Accordingly the protein synthesis expense was calculated as Ksyn
multiplied by the mass of individual proteins.
The above parameters were combined with the GO biological annotations to
infer the ratio of proteome investment and protein synthesis expenses between
organelles.
Functional annotation and enrichment analysis. To annotate protein complexes,
we assembled a list of known stable protein complexes and then annotated proteins
as either being part of these protein complexes (“complex in”, those proteins
involved in protein complex according to either CORUM or reactome data-
bases32,33) or not (“complex out”, other proteins). Note that the “complex out”
group may contain proteins that are actually part of (yet unknown) protein
complexes and that the “complex in” group may contain proteins that not actually
assembled in ﬁbroblasts under the conditions we tested. Despite these limitations,
we assumed that these two groups were enriched for bona ﬁde protein complex and
non-protein complex proteins, respectively.
The GSEA was performed by the online toolkit based on http://babelomics.
bioinfo.cipf.es/ in which the list of proteins (in SwissProt IDs) were ranked with the
T1DS/T2N FC values of transcript, protein, and degradation, and then a logistic
model is used to detect gene sets (functional annotations of GO biological
processes) that are consistently associated to high or low values in the ranked
lists35. The adjusted P-value < 0.05 from the logistic regression was used to
determine the statistical signiﬁcance of GSEA analysis. A total of 651, 1020, and
250 biological processes were identiﬁed to be signiﬁcant at mRNA, protein, and
protein degradation levels. The logarithm odds ratio (LOR) comparing two groups
or experimental conditions was also reported for each processes, LOR> 0 indicates
a functional term is over-represented for genes upregulated in T1DS and LOR< 0
indicates a functional term is over-represented for genes downregulated in T1DS.
DAVID Bioinformatics Resources 6.7 (https://david.ncifcrf.gov/)70 was used to
perform the enrichment analysis of GO biological processes and cellular
component for all the ﬁve segments evenly divided from the T1DS/T2N FC of
protein degradation and to report P-values of enrichment (by a modiﬁed Fisher
exact test). Brieﬂy, all the identiﬁed 4056 proteins were taken as the background for
comparison of proteins in each segment. The P-values of manually compiled
processes showing signiﬁcance (P< 0.05) in any of the segments were used to
indicate the relative enrichment pattern between segments, with a minimum of
four proteins per category. If one category were annotated with <4 proteins in a
segment, statistical insigniﬁcance was assigned (P= 1) for the visualization.
For the further mapping analysis of GO subcellular annotation, bioMart (http://
www.biomart.org/) was used to generate the cellular component for all human
proteins and then ﬁltered based on the identiﬁed protein list. All the offspring GO
items to each organelle were included in the annotation. Those proteins annotated
at multiple cellular components were all accepted and included for the analysis of
each respective component.
Statistics and visualization. We used the boxplot function (R package “graphics”,
default parameters) to generate all the box plots. The box denotes the range of
25–75th percentages. The bold line in the box represents the median of the data
sets. The whiskers are deﬁned as min(max(x), Q_3 + 1.5×IQR) for the upper
whisker and lower whisker: max(min(x), Q_1–1.5×IQR) for lower whisker. Here,
Q_1 and Q_3 represent the 25th and 75th quantiles, respectively, and IQR=Q_3-
Q_1. Outliers were deﬁned based on whisker positions. Wilcox test (wilcox.test in
R) was used to infer P-values.
Networks linking Chr21 proteins and regulated processes. Protein expression
values were log2 transformed. For the unrelated samples, the average of the two
measurements in the replicates was calculated for each protein. Next, a FC was
calculated for each protein by (i) obtaining the median value for the measurements
in normal and in trisomy samples and then (ii) subtracting the median of normal
values from the median of trisomy values. This was done separately for twins and
unrelated samples. In addition, proteins whose quantities strongly varied between
measurements were excluded from further calculations. For this, original (non-
transformed) values of the healthy samples were median-centered and proteins for
which the ratio of the median absolute deviation over median exceeded 0.5 across
measurements were considered to have inherent quantitative variability. This
calculation was done independently for twins and unrelated samples. Proteins
variable in the twins data set were excluded from the calculations there, and
proteins variable in either set were excluded from the top hits in the unrelated
samples. Next, a set of the most highly deregulated proteins in the disease samples
was ﬁrst deﬁned as top 5% proteins with the highest and top 5% proteins with the
lowest FC in the twins samples (406 proteins in total). A set of the same size with
top and bottom 203 proteins with the strongest FCs was then also composed for
the unrelated samples. These two sets were further extended with all measured
proteins from the Chr21. Proteins in the two sets were then annotated with the
reactome pathways they were associated with. Enrichment of particular pathways
in each set was calculated by assessing the over-representation of the term com-
pared to the background of all other measured proteins (excluding highly variable
ones when appropriate). Fisher exact test was used to obtain the associated P-values
and these were further corrected for multiple testing by applying the
Benjamini–Hochberg correction.
The Fig. 4 depicts the reactome process enriched among the highly up- and
downregulated proteins in either the twins or unrelated sets. Only the processes
with the corrected P-value <0.01, containing three or more proteins and having
enrichment higher than 2 over the background proteins are shown. For the
unrelated samples, only two processes passed these criteria; all other proteins
depicted on the ﬁgure represent those strongly deregulated proteins in the
unrelated samples, which are annotated with the terms enriched in the twins
samples selected according to the above criteria. When the same group of proteins
was associated with two or more signiﬁcant reactome terms, the term having a
smaller P-value or containing signiﬁcantly more proteins from the list was selected
as the representative one. Several of the proteins were still annotated with two or
more of the selected terms. In these cases, they are colored according to the term
with the lowest P-value. The names of the proteins encoded on the Chr21 are
shown in red—they were added to the sets even if they were not in the top 5%
deregulated proteins. The border on the circle denotes the direction of
deregulation: upregulated proteins are shown with the black border and
downregulated ones with the light gray border.
Western blots. One-dimensional polyacrylamide gel electrophoresis (1D-PAGE)
was performed by using precast NuPAGE Novex 4–12% Bis–Tris gels (Invitrogen,
Switzerland). About 15 µg of protein was loaded onto each well for the cell lysate.
Proteins were blotted onto a polyvinylidene ﬂuoride (PVDF) membrane (iBlot Dry
Blotting System, Invitrogen), and membranes were blocked with 5% (w/v) non-fat
dry milk in TBST buffer (tris-buffered saline, 0.1% Tween 20) for 1 h at room
temperature and incubated with total OXPHOS Rodent WB Antibody Cocktail
(#ab110413, Abcam, UK) in diluted concentration of 1:1000 at 4 ˚C overnight. This
antibody cocktail contains ﬁve mouse monoclonoal antibodies, one each against CI
subunit NDUFB8 (#ab110242, Anti-NDUFB8 antibody), CII-30 KDa (#ab14714,
Anti-SDHB antibody), CIII-Core protein 2 (#ab14745, Anti-UQCRC2 antibody),
CIV subunit I (#ab14705, Anti-MTCO1 antibody), and CV alpha subunit
(#ab14748, Anti-ATP5A antibody), all from Abcam, UK. Anti-Actin antibody
(#ab3280) was used as a loading control and also purchased from Abcam. Mem-
branes were washed four times for 15 min with TBST buffer and subsequently
incubated with a secondary antibody, Amersham ECL Mouse IgG, HRP-linked
whole Ab (#NA931-100UL, GE Healthcare) at dilutions 1:20,000. The ﬁnal Wes-
tern blot signals were developed with an Amersham ECL Prime Western Blotting
Detection Reagent (GE Healthcare), by chemiluminescence using darkroom
development techniques. Please see uncropped scans of Western blots in Supple-
mentary Fig. 19.
Data availability. All the raw data of mass spectrometry measurements, together
with the input spectral library and OpenSWATH results can be freely downloaded
from ProteomeXchange Consortium (http://proteomecentral.proteomexchange.
org) via identiﬁer PXD004880. Other data are available from the corresponding
authors upon reasonable request.
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